Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

5589 ARTÍCULOS , VIENDO DEL 5371 AL 5385

Bi-phasic dose response in the preclinical and clinical developments of sigma-1 receptor ligands for the treatment of neurodegenerative disorders

Maurice T.

Expert Opin Drug Discov. 2021 Apr;16(4):373-389. doi: 10.1080/17460441.2021.1838483. Epub 2020 Oct 27.

The Peptidyl-prolyl Isomerase Pin1 in Neuronal Signaling: from Neurodevelopment to Neurodegeneration

Fagiani F, Govoni S, Racchi M, Lanni C.

Mol Neurobiol. 2021 Mar;58(3):1062-1073. doi: 10.1007/s12035-020-02179-8. Epub 2020 Oct 21.

Cholesterol metabolism and brain injury in neonatal encephalopathy

Dave AM, Peeples ES.

Pediatr Res. 2021 Jul;90(1):37-44. doi: 10.1038/s41390-020-01218-3. Epub 2020 Oct 26.

Genome-Wide Association Studies of Cognitive and Motor Progression in Parkinson's Disease

Tan MMX, Lawton MA, Jabbari E, Reynolds RH, Iwaki H, Blauwendraat C, Kanavou S, Pollard MI, Hubbard L, Malek N, Grosset KA, Marrinan SL, Bajaj N, Barker RA, Burn DJ, Bresner C, Foltynie T, Wood NW, Williams-Gray CH, Hardy J, Nalls MA, Singleton AB, Williams NM, Ben-Shlomo Y, Hu MTM, Grosset DG, Shoai M, Morris HR.

Mov Disord. 2021 Feb;36(2):424-433. doi: 10.1002/mds.28342. Epub 2020 Oct 28.

24S-hydroxycholesterol: Cellular effects and variations in brain diseases

Sodero AO.

J Neurochem. 2021 May;157(4):899-918. doi: 10.1111/jnc.15228. Epub 2020 Nov 18.

Epigenetic regulators of neuronal ferroptosis identify novel therapeutics for neurological diseases: HDACs, transglutaminases, and HIF prolyl hydroxylases

Rroji O, Kumar A, Karuppagounder SS, Ratan RR.

Neurobiol Dis. 2021 Jan;147:105145. doi: 10.1016/j.nbd.2020.105145. Epub 2020 Oct 28.

Epigenetic mechanisms underlying enhancer modulation of neuronal identity, neuronal activity and neurodegeneration

Alcalà-Vida R, Awada A, Boutillier AL, Merienne K.

Neurobiol Dis. 2021 Jan;147:105155. doi: 10.1016/j.nbd.2020.105155. Epub 2020 Oct 27.

Miro (Mitochondrial Rho GTPase), a key player of mitochondrial axonal transport and mitochondrial dynamics in neurodegenerative diseases

Panchal K, Tiwari AK.

Mitochondrion. 2021 Jan;56:118-135. doi: 10.1016/j.mito.2020.10.005. Epub 2020 Oct 28.

Movement Disorders in Chronic Kidney Disease - A Descriptive Review

Safarpour Y, Vaziri ND, Jabbari B.

J Stroke Cerebrovasc Dis. 2021 Sep;30(9):105408. doi: 10.1016/j.jstrokecerebrovasdis.2020.105408. Epub 2020 Nov 1.

Quantitative neurotoxicology: Potential role of artificial intelligence/deep learning approach

Srivastava A, Hanig JP.

J Appl Toxicol. 2021 Jul;41(7):996-1006. doi: 10.1002/jat.4098. Epub 2020 Nov 2.

Advances in nanomedicines for diagnosis of central nervous system disorders

Zhang X, Zhou J, Gu Z, Zhang H, Gong Q, Luo K.

Biomaterials. 2021 Feb;269:120492. doi: 10.1016/j.biomaterials.2020.120492. Epub 2020 Oct 24.

Targeting microglial autophagic degradation in NLRP3 inflammasome-mediated neurodegenerative diseases

Wu AG, Zhou XG, Qiao G, Yu L, Tang Y, Yan L, Qiu WQ, Pan R, Yu CL, Law BY, Qin DL, Wu JM.

Ageing Res Rev. 2021 Jan;65:101202. doi: 10.1016/j.arr.2020.101202. Epub 2020 Nov 5.

The Pharmacological Case for Cannabigerol

Nachnani R, Raup-Konsavage WM, Vrana KE.

J Pharmacol Exp Ther. 2021 Feb;376(2):204-212. doi: 10.1124/jpet.120.000340. Epub 2020 Nov 9.

Cell therapy in Huntington's disease: Taking stock of past studies to move the field forward

Bachoud-Lévi AC, Massart R, Rosser A.

Stem Cells. 2021 Feb;39(2):144-155. doi: 10.1002/stem.3300. Epub 2020 Nov 25.

Emerging potential of cannabidiol in reversing proteinopathies

Dash R, Ali MC, Jahan I, Munni YA, Mitra S, Hannan MA, Timalsina B, Oktaviani DF, Choi HJ, Moon IS.

Ageing Res Rev. 2021 Jan;65:101209. doi: 10.1016/j.arr.2020.101209. Epub 2020 Nov 9.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias